CBD has become ubiquitous in recent years, both as an extract unto itself and in the form of food and drinks infused with the substance. Given its widespread uses, it’s not hard to see why it’s become so popular. But it turns out that CBD is not universally beloved — and one of its opponents has the ability to make life a lot harder for the nascent industry.
That would be the FDA, who issued warning letters to over a dozen companies this week.
At The Washington Post, Laura Reiley has the story. “This week the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing CBD, saying they had violated the Federal Food, Drug and Cosmetic Act,” she writes.
CBD distribution can vary from state to state. To cite one example, a report from NJ.com notes that, of the 15 companies cited, only 3 have products sold within New Jersey. (There’s probably a “garden state” pun to be made here.)
Reiley’s article emphasizes the paradox of the FDA’s approach: numerous companies had waited for specifics from the agency regarding its views on CBD, as opposed to this more confrontational approach.
Reiley also reports that the companies cited will have 15 days to respond to the FDA’s letter. What’s at stake might not just apply to a small group of companies, but an entire industry — one whose future looks a little more vague than it did a week ago.
Subscribe here for our free daily newsletter.
Whether you’re looking to get into shape, or just get out of a funk, The Charge has got you covered. Sign up for our new wellness newsletter today.
